NL-OMON47707招募中不适用
A phase I study to investigate the safety of TEG001 cell suspension for infusion in patients with relapsed/refractory Acute Myeloid Leukemia/high-risk Myelodysplastic Syndrome (IPSS-R score >4,5) relapsed/refractory or Multiple Myeloma - TEG001
niversitair Medisch Centrum Utrecht0 个研究点目标入组 18 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Age >= 18-years
- •- Relapsed/refractory Acute Myeloid Leukemia/ high-risk Myelodysplastic
- •Syndrome (IPSS-R >4.5) or relapsed/refractory Multiple Myeloma, for which no
- •remaining standard of care or approved treatment options are available
排除标准
- •- In the investigators judgment, the subject is unlikely to complete all
- •protocol-required study visits or procedures
- •- Other concurrent malignancy requiring treatment
- •- Active endogenous retrovirus
- •- Active GVHD and/or systemic immune suppression for GVHD
- •- Uncontrolled infections
- •- Inadequate renal, hepatic, pulmonary and cardiac function
- •- Pregnant or lactating women
研究者
相似试验
招募中
不适用
Safety of TEG001 in patients with r/r AML, high-risk MDS or MMNL-OMON25189niversity Medical Center Utrecht18
招募中
1 期
Phase I study for the efficacy and the safety of the perioperative urinastatin therapy in chest surgical patients with interstitial pneumonia.interstitial pneumonia, lung cancer, metastatic lung tumor, pneumothoraxJPRN-UMIN000003295Tokyo Women's Medical University of Medicine, Department of Surgery I30
尚未招募
1 期
Investigating targEting LysyL oxIdase tO ameliorate scarring in burn Traumaburn injurySkin - Other skin conditionsInjuries and Accidents - BurnsACTRN12623001071617university of western australia60
终止
1 期
A first-in-human study of VG161 in participants with advanced malignant tumours that have not responded to conventional therapies.Advanced malignant solid tumorsCancer - Other cancer typesCancer - Any cancerACTRN12620000244909Virogin Biotech Australia Pty. Ltd.7
终止
1 期
This study is examining the safety and tolerability of a new drug (Everolimus) in combination with chemotherapy in the treatment of relapsed adult acute lymphobastic leukaemiaacute lymphobastic leukaemia (ALL)Cancer - Leukaemia - Acute leukaemiaACTRN12610000405011Australasian Leukaemia and Lymphoma Group20